Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TriPath Imaging

This article was originally published in The Gray Sheet

Executive Summary

FDA will not approve firm's PMA supplement to allow screening of AutoCyte PREP thin-layer preparation slides on the AutoPap system until it has fully investigated assertions made by a former employee questioning the use of the AutoPap to screen thin-layer preparations, firm announces April 2. An internal investigation has determined the assertions to be false, company manitains. Supplement was originally filed in October 1999. Additional data from a prospective, masked trial was submitted to FDA in December. TriPath may accept limitations in proposed product labeling to secure faster approval of the supplement, or choose to "collect additional data to support the current labeling proposal"

Related Content

UsernamePublicRestriction

Register

MT014730

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel